Nemucore Announces Publication in Tissue Barriers

WORCESTER, Mass. - Oct. 2, 2014 - PRLog -- Nemucore Medical Innovations, Inc., a privately-held biopharmaceutical company dedicated to the development and commercialization of targeted therapies to treat patients afflicted with multidrug resistant cancers, today announced the publication of its paper titled "Pathogen-Inspired Drug Delivery to the Central Nervous System” in the journal Tissue Barriers. Nemucore’s Joseph Cacaccio, Eileen Wrabel, and Timothy Coleman of Nemucore authored the publication in collaboration with Rebecca McCall and Rachael Sirianni of Barrow Neurological Institute (BNI). The research discussed In the paper resulted from a collaboration between Nemucore, the Translational Genomics Research Institute, and BNI with funding from the Ben and Catherine Ivy Foundation to further development of new life-saving treatments for glioblastoma.

Drug delivery across the blood brain barrier remains a critical barrier facing the development of effective treatments for diseases of the central nervous system. However, many viruses, bacteria, and neurotoxins have adapted methods for passing through the blood brain barrier and into the central nervous system. The adaption of these pathological mechanisms has the potential to vastly improve delivery of therapies and to facilitate the translation of novel therapeutics to the clinic. The goal of the work between Nemucore and BNI is to identify these ligand-mediated strategies to improve the brain-specific delivery of engineered nanocarriers, including polymers, lipids, biologically sourced materials, and imaging agents.

Nemucore's is currently developing NMI-800, a personalized medicine that targets glioblastoma, the most common and aggressive of brain tumors. "The ideas discussed in this publication are an attainable vision for the future of molecularly-targeted therapeutics to treat central nervous system diseases and cancers," said Timothy Coleman, Ph.D. Nemucore’s CEO. "Furthermore, this review paper highlights the strategies nature has adopted to circumvent the blood brain barrier that we can engineer into our drug delivery strategies.  ‘Biomimicry’ is an essential tool in our approach to overcome many physiological barriers."

---

About Nemucore Medical Innovations, Inc.

Nemucore is dedicated to designing, investigating, developing, and commercializing life-saving novel therapeutics for the treatment of ovarian cancer and other unmet medical needs. Ultimately, Nemucore’s products will be part of the personalized medicine revolution occurring in cancer therapies. Our unique focus on reducing the complex nature of manufacturing is expected to enhance the speed by which we translate novel therapeutics to the clinic. As a participant in the National Cancer Institute's Centers for Cancer Nanotechnology Excellence, we are building a state of the art biomanufacturing facility as a national resource for nanomedicine and emerging biopharmaceutical community. Nemucore was founded in 2008 and is based in Worcester, Massachusetts. For more information, please visit http://www.nemucore.com.

Forward-looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.